文献速递中医内科中药与中成药合理使用

加减知柏地黄丸对系统性红斑狼疮激素撤减的系统评价与Meta分析

Modified Zhibai Dihuang pill, a traditional Chinese medicine formula, on steroid withdrawal in systemic lupus erythematosus: A systematic review and meta-analysis.
PubMed 文献 · J Integr Med · 2020-08-26

该系统评价纳入20项随机对照试验共1470例SLE患者,评估加减知柏地黄丸辅助激素撤减的疗效。Meta分析显示联合标准治疗较单用标准治疗可更大程度减少激素剂量(WMD: 3.79; 95% CI: 2.58-5.01; P < 0.001),SLEDAI及补体C3等次要结局亦见改善,且耐受性良好。结论为初步证据支持知柏地黄丸作为SLE激素撤减的辅助治疗。

要点

  • 加减知柏地黄丸联合标准治疗可使SLE患者激素剂量进一步减少(WMD: 3.79; 95% CI: 2.58-5.01; P < 0.001)。
  • 次要结局SLEDAI及补体C3亦见有利改善,且未增加不良事件。
  • 证据仅为初步,需更严格研究验证并探索知柏地黄丸活性成分机制。

核心结论

  • 该系统评价提供初步证据支持知柏地黄丸作为辅助治疗用于SLE患者激素剂量撤减,但需更严格研究验证并探索其活性成分机制。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase、Cochrane Central Register of Controlled Trials、中国生物医学文献数据库、中国知网、维普和万方数据库,从建库至2019年6月1日。
  • 纳入20项随机对照试验,共1470例SLE患者;试验组以知柏地黄丸为基础加减作为辅助治疗,对照组包含激素。
  • 主要结局为激素剂量变化,次要结局包括SLEDAI、疾病活动度生物标志物和临床应答率,采用STATA 15.0分析,效应量以WMD或OR及95%CI表示。

主要发现

  • 加减知柏地黄丸联合标准治疗较单用标准治疗可更大程度减少激素剂量(WMD: 3.79; 95% CI: 2.58-5.01; P < 0.001)。
  • 次要结局如SLEDAI和补体C3亦见有利结果。
  • 加减知柏地黄丸治疗耐受性良好,未增加不良效应。

关键数值与推荐

  • 纳入标准为评估SLE患者激素剂量减少的随机对照试验,试验组中药方剂须以知柏地黄丸为基础加减并作为辅助治疗,对照组须包含激素。
  • 主要结局激素剂量变化的合并效应为WMD: 3.79; 95% CI: 2.58-5.01; P < 0.001,支持联合治疗组激素减少更多。

临床怎么用

  • 在SLE标准治疗基础上,可考虑联合加减知柏地黄丸以辅助激素剂量撤减,并监测SLEDAI及补体C3等指标。
  • 联合治疗耐受性良好,但需注意现有证据仅为初步,临床决策应结合更严格研究及个体化评估。

局限性

  • 结论基于初步证据,需更多严格设计的研究验证。
  • 知柏地黄丸相关活性成分的作用机制尚未探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Zhibai Dihuang pill (ZBDH), a Chinese herbal formula, has been widely used as an adjunctive therapy to help reduce the patient's steroid dose and maintain low disease activity in systemic lupus erythematosus (SLE). OBJECTIVE: This systematic review evaluates the therapeutic effect of modified ZBDH in reducing steroid use in patients with SLE. SEARCH STRATEGY: A systematic literature search was carried out using seven databases, including PubMed, Embase, Cochrane Central Register of Controlled Trials, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, Chinese VIP Information and Wanfang Database, from their inception to June 1st, 2019. The search terms included "systemic lupus erythematosus," "Chinese medicine" and "clinical trial," and their synonyms. Subject headings matching the above terms were also used. INCLUSION CRITERIA: This meta-analysis included randomized controlled trials that evaluated the reduction of steroid dose in patients with SLE. Traditional Chinese medicine (TCM) formulas in experimental group should be prescribed based on ZBDH and used as adjunctive therapy and the comparator should contain steroids. DATA EXTRACTION AND ANALYSIS: Two authors independently conducted database search, study selection, data extraction and quality assessment. The extracted information contained study design, sample size, recruitment mode, diagnostic criteria, inclusion and exclusion criteria, participant characteristics, TCM patterns, TCM formulas and treatment outcomes. The primary outcome was the change of steroid dose. Secondary outcomes included SLE Disease Activity Index (SLEDAI), biomarkers of disease activity and clinical response rate. STATA 15.0 was used to analyze the pooled effects reported as weighted mean difference (WMD) or odds ratio, with a 95% confidence interval (CI). RESULTS: In total, 20 trials involving 1470 SLE patients were included. The pooled result showed that modified ZBDH taken in combination with standard care led to a larger reduction in steroid dose, compared to standard care alone (WMD: 3.79; 95% CI: 2.58-5.01; P < 0.001). Favorable outcomes were also seen in secondary outcome criteria, such as SLEDAI and complement 3. The modified ZBDH treatments were well tolerated without increasing adverse effects. CONCLUSION: The systematic review provided preliminary evidence supporting the use of ZBDH as a co-therapy to aid steroid dose reduction in patients with SLE. However, more rigorous studies should be conducted to validate these findings, and explore the mechanisms of ZBDH's relevant bioactive constituents.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Dai L, Chan KK, Mao JC, et al. Modified Zhibai Dihuang pill, a traditional Chinese medicine formula, on steroid withdrawal in systemic lupus erythematosus: A systematic review and meta-analysis. J Integr Med. 2020. PMID: 32907784. doi:10.1016/j.joim.2020.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。